By: IPP Bureau
Last updated : August 21, 2026 8:21 am
The company plans to use the new funding to accelerate Minima's expansion into international markets following its US FDA premarket approval (PMA) in August 2024
California-based medical device company Renata Medical has raised $25 million in a Series D financing round to support the international commercialisation of its paediatric stent system and advance its pipeline of congenital heart disease technologies.
The round was led by private equity firm Archimed, with participation from Renata's existing investors.
Renata's lead product, Minima, is a balloon-expandable growth stent designed specifically for children and young patients with congenital heart defects, including pulmonary artery stenosis and coarctation of the aorta.
The company plans to use the new funding to accelerate Minima's expansion into international markets following its US FDA premarket approval (PMA) in August 2024. The device was evaluated in the GROWTH pivotal trial, which enrolled 42 patients.
According to trial results cited by the company, 97.6% of patients experienced effective stenosis relief, while 100% remained free from additional surgical intervention six months after implantation.
Minima is designed to address a key challenge in paediatric interventional cardiology: treating children whose blood vessels are too small for many conventional devices.
The stent can be crimped to less than 2 mm for delivery through a small catheter inserted via a vein or artery in the groin or neck.
Unlike conventional fixed-size stents, Minima is designed to expand as the child grows, potentially reducing the need for repeat procedures as children mature.
"Adoption of the Minima stent system has exceeded our expectations since commercial launch in 2024," said Dustin Armer, CEO, Renata Medical.
The company will also direct part of the financing towards developing additional paediatric-specific technologies for congenital heart disease and generating further clinical evidence for Minima as adoption expands.
André-Michel Ballester, Managing Partner at Archimed and former CEO of LivaNova, said the investment reflects the opportunity to develop therapies specifically designed for children with congenital heart defects, who have historically been treated with devices developed primarily for adults.